Why Immunome Is Back on Investor Radars

Immunome (IMNM) has moved into focus after encouraging phase III data for its lead oncology candidate varegacestat, preparations for a potential FDA filing, higher earnings estimates, and fresh insider buying by the CEO.

At a share price of US$21.84, Immunome has seen a 7.01% 7 day share price return and a 4.90% 90 day share price return. Its 1 year total shareholder return of 250% and 3 year total shareholder return of around 3x point to strong momentum that recent insider buying and positive varegacestat news have brought back into focus.

If this kind of renewed interest in oncology and AI driven drug development has your attention, it could be a good time to scan other opportunities with 37 healthcare AI stocks

With shares at US$21.84 and trading at a large discount to the US$35.54 analyst price target and an intrinsic value estimate implying a very wide gap, investors have to ask: is Immunome mispriced, or is the market already baking in future growth?

Preferred Price-to-Book of 3.9x: Is it justified?

Immunome trades on a P/B of 3.9x, slightly above its direct peers at 3.8x and well above the broader US Biotechs average of 2.3x, so the market is assigning a premium to its balance sheet today.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For early stage biotech names that are loss making, P/B is often used instead of earnings based multiples because profits are not yet available to anchor valuation.

In Immunome’s case, a 3.9x P/B alongside ongoing losses and a negative return on equity of 33.48% suggests investors are paying more than the sector average for each dollar of net assets. At the same time, the SWS DCF model flags the shares as trading 87.7% below an estimated future cash flow value of $177.14 per share. This presents a very different view of potential value based on that model.

Compared with the US Biotechs P/B average of 2.3x, Immunome’s 3.9x ratio stands out as expensive on a simple balance sheet comparison, indicating a stronger market expectation than is applied to the sector overall.

Result: Price-to-book of 3.9x (OVERVALUED).

However, the story still carries clear risks, including ongoing losses with net income at a US$212.394 million loss and reliance on successful oncology trial progress.

Another View: DCF Paints a Very Different Picture

While the 3.9x P/B ratio makes Immunome look expensive against peers, the SWS DCF model points the other way entirely. It shows an estimated future cash flow value of $177.14 per share versus today’s $21.84 price, indicating that the stock is trading at a very wide discount. Which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals from valuation models and ongoing clinical risks and rewards in play, it may be helpful to review the numbers yourself and decide where you stand. To see both sides in one place, start with 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If Immunome has sharpened your interest, now is the moment to widen the net and line up a few more candidates that could deserve your attention.

• Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems, where strong fundamentals meet under-the-radar names that many investors are not watching yet.
• Strengthen your core holdings by filtering for companies via the solid balance sheet and fundamentals stocks screener (39 results), focusing on businesses with financial footing that can support their plans.
• Dial down portfolio stress by checking the 67 resilient stocks with low risk scores for names with lower risk scores that may help smooth out the sharper moves in your other positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.